Business Wire

CAP Opens Comment Period for MMR/MSI Testing, Advancing Care for Patients with Cancer

NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
Seeking Alpha

Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) ...
Healio

Study shows disparities in access to molecular diagnostics for colorectal cancer

Please provide your email address to receive an email when new articles are posted on . Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced ...
Nasdaq

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 ...
Business Wire

Groundbreaking CAP Guideline Clarifies Biomarker Testing, Impacts Multiple Cancer Types

NORTHFIELD, Ill.--(BUSINESS WIRE)--A new College of American Pathologists (CAP) evidence-based guideline is among the first to address testing based less on the cancer type or tumor origin and more on ...
ascopubs.org

Overlooking MMR deficiency in carriers of certain pathogenic variants by routine MSI and/or IHC testing in Lynch syndrome: Implications for a wider MMR deficiency testing.

A novel xenonucleic acid mediated molecular clamping technology for early colorectal cancer diagnostics. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not ...